drugset / Trial / NCT00827931

Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery

NCT00827931 ↗

Phase 4 Completed 94 enrolled Pfizer
RandomizedParallel-groupOpen-labelPrevention

Summary

Tranexamic acid has been shown to reduce postoperative blood losses and transfusion requirements in various types of major surgery (orthopedic surgery, spine surgery, cardiopulmonary bypass, liver resections, and gynecological cancers).The current trial is being conducted to compare the efficacy of tranexamic acid plus standard of care versus standard of care in reduction of blood loss in patients undergoing major abdominal surgeries.

Timeline

Start
2009-09
Primary completion
2011-04
Completion
2011-05

Outcome

Missed primary endpoint

registry Tranexamic Acid Plus Standard of Care vs Standard of Care; p = 0.460; Mean Difference (Final Values) -99.9 NCT00827931 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 15 mg/kg Intravenous

Indications

No indication recorded.